Introduction
Coronavirus disease 2019 (COVID-19) is a newly emerged viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [
1]. COVID-19 is highly contagious and has become pandemic quickly. Innate and adaptive immune responses are activated in COVID-19 patients, perhaps uncontrolled innate and adaptive immune responses may lead to locally and systemically tissue damage. Recently, the alterations of lymphocyte subsets in COVID-19 patients had attracted the attention of researchers for exhausted lymphocytes were a feature of severe COVID-19 [
2‐
4]. An overall decline of lymphocyte subsets including CD4
+ T cells, CD8
+ T cells, B cells, and NK cells has been reported in severe and deceased COVID-19 patients [
5,
6]. However, vary patterns of lymphocyte subsets abnormality in severe COVID-19 patients also have been demonstrated by other studies [
7‐
10]. Reports involving the change of CD4
+ to CD8
+ T cells ratio were also inconsistent [
9,
11,
12]. Thus, the reported patterns of lymphocyte subsets in patients with COVID-19 were diverse and controversial, and necessitated to clear more.
Lung computed tomography (CT) plays an important role in the early diagnosis and evaluating the disease severity of COVID-19 for different imaging manifestations are demonstrated at different stages of the disease [
13]. At the early stages of the COVID-19, unilateral or bilateral ground-glass opacity (GGO) is most common in the posterior aspects and periphery of the lungs. With the progression of the disease, the scope and number of GGO are gradually expanding and fusion. At the later stages of the COVID-19, crazy paving appearance and pulmonary consolidation begin to appear and are gradually extensive. As far, the correlation of lymphocyte subsets with the lesion manifestation in lung CT was not be well documented and necessitated to clarify.
Here, we first investigated alterations of lymphocyte subsets in severe COVID-19 patients. Then, we observed the correlations of lymphocyte subsets with the number, quadrant, and area of lesions in lung CT. Finally, we investigated the impacts of the lymphocyte subsets in patients with delayed hospitalization.
Method
Patients
One hundred and six COVID-19 patients who were confirmed by positive RNA of SARS-CoV-2 using throat swab specimens were prospectively recruited from June 23, 2020 to February 29, 2020 at the First Affiliated Hospital, Nanchang University. Patients were stratified at their admission, 33 patients with severe COVID-19 was diagnosed according the guideline of the American Thoracic Society and Infectious Diseases Society of America [
14]. 73 cases not meeting the criteria were classified as mild COVID-19. All procedures followed were in accordance with the Ethics Committees of the First Affiliated Hospital, Nanchang University, and with the Helsinki Declaration of 1975, as revised in 2000. All patients enrolled in study were over 16 years old, and written informed consent was obtained from themselves or their legal representatives.
Data acquisition
Data on the demography, epidemiology, symptoms and signs, laboratory tests, as well as radiography findings were extracted from electronic medical records using a predesigned datasheet. All laboratory tests were conducted in the Central Clinical Laboratory of the First Affiliated Hospital, Nanchang University and were adopted if they were performed with fasting blood samples at patients’ admission.
Flow cytometry
Anticoagulated peripheral blood samples with EDTA were collected from COVID-19 patients at their admission and tested within 6 h. Lymphocyte subsets was performed by Cytomics FC 500 flow cytometer and analysed by CXP Analysis software (Beckman Coulter, Brea, California). Anti-CD3 was conjugated by PE-texas red (ECD), anti-CD4, anti-CD8, anti-CD19 were conjugated by fluorescein isothiocyanate (FITC), PE-Cy5 (PC5), and R-phycoerythrin (PE) respectively. The count of NK cell marked by CD3−CD16+CD56+ was auto calculated CXP Analysis software. All tests were performed according to the manufacturer’s instructions.
Statistics
Statistical analysis was performed with SPSS 25.0 (SPSS, Inc., Chicago, USA) and MedCalc (MedCalc Software Ltd., Ostend, Belgium). Continuous data were expressed as the mean ± standard deviations or medians with quartile (P25-P75) and categorical data were expressed as numbers (%). The Student’s t-test was used for continuous data distributed normally, and the Mann–Whitney U test was used for continuous data distributed abnormally. The χ2 or Fisher’s tests were used for categorical data. Rank correlation was analysed using the Spearman method. A p values of less than 0.05 was considered statistically significant. Independent risk factors were identified using multivariate logistic regression according to the forward Wald method, with entry and removal probabilities of 0.05 and 0.10, respectively.
Discussion
COVID-19 continuously threated public health heavily, which required more bench and clinic studies to profile this disease more profoundly. The common symptoms in COVID-19 patients, in accordance with previous reports [
2,
15,
16], were fever, and followed by dry cough, and chest tightness. Similar with studies investigated in other area [
17,
18], the age of patients in this study was dramatically younger than those in Wuhan. Notably, the frequencies of hypertension and diabetes for COVID-19 patients in this study were also much lower than patients in Wuhan [
2,
15,
19]. The underlying reason may interpret by the lower age. Present study showed that there are 11.3% patients accompanying with bacterial infection, which suggested more attention should be paid to the evaluation of bacterial infection on patients’ admission. Additionally, present study found the risk of severe COVID-19 in patients with comorbidities is much higher (HR = 2.546) than those who without comorbidities. More importantly, present study found that the reason why patients with comorbidities were prone to severe COVID-19 were independent of their basic lymphocyte status (Fig.
2).
Complex immune dysregulation has been found in COVID-19 patients [
20]. Currently, the change patterns of lymphocyte subsets were not conclusive. It is reported [
5,
6] that a whole decline of lymphocyte subsets including CD4
+ and CD8
+ T cells, B cells, and NK cells were presented in severe and deceased COVID-19 patients. Liu et al. [
10] suggested CD8
+ T cell count was significant decreased in severe COVID-19 patients than mild patients at the time point of disease onset and 7–9 days later, but their difference in CD4
+ T cell count was not significant at any time point. studies [
7‐
9] also indicated decreased CD4
+ and CD8
+ T cells were correlated with disease severity of COVID-19, but there is no difference for the level of B or NK cell between severe and mild COVID-19 patients. Additionally, reports involving the change of CD4
+ to CD8
+ T cells ratio were also inconsistent [
9,
11,
12]. In this study, we found the significant percentage change of lymphocyte subsets is rare no matter in patients with severer clinical type or more extensive CT manifestation. These findings were agreement with previous studies [
4,
7]. It is noteworthy that the T cell and CD4
+ T cell but not CD8
+ T cell were significantly decreased in severe COVID-19 patents, which suggested that CD4
+ T cell but not CD8
+ T cell play more important role in immunity response to SARS-CoV-2 infection. Studies using SARS-CoV or MERS-CoV infected mouse demonstrated that depletion of CD4
+ T cells but not CD8
+ T cells would lead to delayed clearance of virus and enhanced immune-mediated pneumonitis [
21,
22]. Similarly, high-level CD4
+ but not the CD8
+ T cell response was also observed in SARS patients [
23]. What is more, the significantly decreased B cell in severe COVID-19 patents indicated that humoral immunity has been attenuated in antiviral response of SARS-CoV-2. It has reported [
24‐
26] that T-helper type 1 (Th1), T-helper type 2 (Th2), and regulatory T cells were varying degrees of activated in peripheral blood from critical COVID-19 patients after stimulation with specific antigen of SARS-CoV-2. It can be speculated all the CD4
+ T cell subgroups were exhaust in blood of critical COVID-19 patients for the severely damaged lymphoid organs and/or exudation of circulating lymphocytes into lung [
9], although the alteration of CD4
+ T cell subsets warrants further investigation.
With regard to lymphocyte subset changes with CT manifestation, present study found that the total lymphocyte counts were gradually decreased with the increased number, infiltrated quadrants of lesions, and the area of the maximum lesion. T cell counts were gradually decreased with the increase of infiltrated quadrants of lesions and the area of the maximum lesion rather than the increased lesion number. Gradually decreased CD4+ and CD8+ T cell counts were only observed with increased area of the maximum lesion. Those results revealed that the area of the maximum lesion was closer correlated with the count of lymphocyte subsets and was more appropriate to estimate the severity of COVID-19.
The alteration of lymphocyte subsets with the delayed hospitalization has not been reported before, present study firstly observed their correlation and found that the total lymphocyte, T cell, CD4
+ and CD8
+ T cell counts were gradually decreased with the the increased TOH for all enrolled COVID-19 patients. The same results were observed in severe patients but not observed in mild patients (Fig.
5). Those findings indicated that the lymphatic organs will continue to be damaged for severe patients if there is no intervention. Liver was a predominantly vulnerable extrapulmonary organ in patients with COVID-19, hepatic dysfunction was seen in 14–53% of cases and particularly in those with severe condition [
27]. Similar with the trends of lymphocyte subsets, present study also found the level of ALT was gradually elevated with the TOH (Fig.
6), suggested that delayed hospitalization may cause more liver injure. Therefore, early hospitalization could avoid disease aggravation and the unnecessary use of scarce medical resources.
There were several limitations in this study. First, the alteration of CD4+ T cell subsets was not investigated, although CD4+ T cell was demonstrated to be mainstay of immunity response to severe SARS-CoV-2 infection. Second, only 3 cases with TOH more than 14 days (TOH was 15, 15, and 16 days, respectively), the lymphocyte subset alterations in convalescence of COVID-19 patients were not seen in this study. More studies including patients with TOH more than 14 days need to investigate to observe lymphocyte subset alterations in whole natural history of the disease.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.